Baseline and 2-year differences in spinal symptoms and spinal and hip mobility in early axial spondyloarthritis and non-axial spondyloarthritis chronic back pain patients
Authors:
- Ana Bento da SilvaASAna Bento da Silva
- Sofia RamiroSRSofia Ramiro
- Miranda van LunterenMLMiranda van Lunteren
- Mary Lucy MarquesMMMary Lucy Marques
- Marleen van de SandeMSMarleen van de Sande
- Camilla FongenCFCamilla Fongen
- Sofia ExarchouSESofia Exarchou
- Roberta RamondaRRRoberta Ramonda
- Désirée van der HeijdeDHDésirée van der Heijde
- Floris A van GaalenFGFloris A van Gaalen
Open Access
Abstract
Objective To compare spinal symptoms and spinal/hip mobility at baseline and 2 years in early axial spondyloarthritis (axSpA) and non-axSpA chronic back pain (BP) patients. Methods Baseline and 2 years data of the SPondyloarthritis Caught Early cohort were analysed. Outcomes assessed: overall BP, BP at night, morning stiffness (MS) intensity, MS duration, occiput-to-wall distance (OWD), cervical rotation, chest expansion, lateral spinal flexion (LSF), modified Schober test (mSchober), intermalleolar distance (IMD) and Bath Ankylosing Spondylitis Metrology Index (BASMI). Linear or zero-inflated negative binomial regression was used to compare 2 years outcomes between groups (adjusting for baseline value, sex, age and use of non-steroidal anti-inflammatory drugs). Results There were 294 axSpA and 123 non-axSpA patients (mean symptom duration: 13 months). At baseline, non-axSpA patients had worse symptoms and mobility, except OWD (eg, mean(SD): BP at night 3.6 (2.9) axSpA vs 4.6 (2.7) non-axSpA; OWD 0.5 (1.2) vs 0.1 (0.7)). After 2 years, all symptoms and cervical rotation significantly improved in both groups, but LSF and mSchober only in axSpA. In multivariable analyses, axSpA was associated with larger improvements in BP at night (β (95% CI): −0.85 (−1.47; −0.23)), mSchober (0.26 (0.03; 0.50)), IMD (4.86 (1.93; 7.80)) and BASMI (−0.24 (−0.41; −0.08)), and with lower likelihood of a normal OWD (OR (95% CI): 0.09 (0.01; 0.83)). Conclusion Over 2 years, all spinal symptoms and some mobility measures improved in both groups, but impairments remained prevalent (particularly in non-axSpA). Nevertheless, axSpA was associated with larger improvements in BP at night, mSchober, IMD and BASMI, but with more OWD impairment.Keywords
This publication has 53 references indexed in Scilit:
- Measuring Outcomes in Axial SpondyloarthritisArthritis Care & Research, 2020
- Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial SpondyloarthritisArthritis Care & Research, 2016
- Spinal Mobility in Axial Spondyloarthritis: A Cross‐Sectional Clinical StudyMusculoskeletal Care, 2016
- Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve‐Year DataArthritis Care & Research, 2015
- Clinical course of non‐specific low back pain: A systematic review of prospective cohort studies set in primary careEuropean journal of pain, 2012
- A systematic review of the global prevalence of low back painArthritis & Rheumatism, 2012
- Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- Clinically important outcomes in low back painBest Practice & Research Clinical Rheumatology, 2005
- Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo‐controlled trial (ASSERT)Arthritis & Rheumatism, 2005
- Health-related quality of life in ankylosing spondylitis: A survey of 175 patientsArthritis & Rheumatism, 1999